The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Albert Salehi

S Albert Salehi

Research team manager

Albert Salehi

An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans

Author

  • Stefan Amisten
  • S Albert Salehi
  • Patrik Rorsman
  • Peter M. Jones
  • Shanta J. Persaud

Summary, in English

G-protein coupled receptors (GPCRs) regulate hormone secretion from islets of Langerhans, and recently developed therapies for type-2 diabetes target islet GLP-1 receptors. However, the total number of GPCRs expressed by human islets, as well as their function and interactions with drugs, is poorly understood. In this review we have constructed an atlas of all GPCRs expressed by human islets: the 'islet GPCRome'. We have used this atlas to describe how islet GPCRs interact with their endogenous ligands, regulate islet hormone secretion, and interact with drugs known to target GPCRs, with a focus on drug/receptor interactions that may affect insulin secretion. The islet GPCRome consists of 293 GPCRs, a majority of which have unknown effects on insulin, glucagon and somatostatin secretion. The islet GPCRs are activated by 271 different endogenous ligands, at least 131 of which are present in islet cells. A large signalling redundancy was also found, with 119 ligands activating more than one islet receptor. Islet GPCRs are also the targets of a large number of clinically used drugs, and based on their coupling characteristics and effects on receptor signalling we identified 107 drugs predicted to stimulate and 184 drugs predicted to inhibit insulin secretion. The islet GPCRome highlights knowledge gaps in the current understanding of islet GPCR function, and identifies GPCR/ligand/drug interactions that might affect insulin secretion, which are important for understanding the metabolic side effects of drugs. This approach may aid in the design of new safer therapeutic agents with fewer detrimental effects on islet hormone secretion. (C) 2013 Elsevier Inc. All rights reserved.

Department/s

  • Islet cell physiology
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2013

Language

English

Pages

359-391

Publication/Series

Pharmacology and Therapeutics

Volume

139

Issue

3

Document type

Journal article review

Publisher

Elsevier

Topic

  • Pharmacology and Toxicology

Keywords

  • Human islets of Langerhans
  • G-protein coupled receptors
  • GPCRome
  • Islet
  • hormone secretion
  • GPCR drug targets

Status

Published

Research group

  • Islet cell physiology

ISBN/ISSN/Other

  • ISSN: 0163-7258